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Pharmacy Benefit Managers
Overview—This issue brief uses large employer experi-
ences with pharmacy benefit managers (PBMs) to shed
light on their potential as Medicare outpatient drug
benefit administrators. PBM management techniques
and typical employer approaches are discussed, as well
as employer perspectives on PBM strengths and weak-
nesses and lessons learned. Considerations for Medi-
care policy are also examined. Information is based on
a literature review and conversations and telephone
interviews with employers, PBM industry executives,
and benefit consultants. This brief builds on previous
National Health Policy Forum PBM industry analysis;
in particular the October 1999 forum and issue brief
“The ABCs of PBMs.”1
Pharmacy benefit managers (PBMs) are central to
the debate over a Medicare prescription drug benefit.
Virtually all the major proposals include PBMs to
administer the benefit, with some analysts citing the
method as an alternative to price regulation.2 But not all
PBMs are alike.
The industry, which administers drug benefits for
more than 200 million people nationwide, is varied and
changing.3 PBMs provide a wide array of services,
employ different management strategies, and operate in
a very complex pharmaceuticals market. In recent years,
the PBM industry has gone through dramatic consolida-
tion.4 Now, the three largest firms handle more than
three-quarters of retail prescription drug purchases.5
Large self-insured employers turned to PBMs during
the 1990s to administer the popular drug benefit, manage
cost and utilization trends, ensure appropriate use of
drugs, and improve care quality. Although most employ-
ers are satisfied with their PBM, concern is growing as
drug spending continues to climb at double-digit rates.
Employer frustration over rising costs and questions
about appropriateness of drug use are stimulating interest
in PBM contractual relationships, especially financial
arrangements with drug manufacturers, and the bearing
those relationships may have on PBM performance.
Amidst a growing public discourse about drug
spending and affordability, Congress is considering a
Medicare benefit. Whether the best practices of private-
sector pharmacy benefit management are appropriate
for Medicare is uncertain. PBMs rely on utilization
controls, especially techniques that promote formulary
compliance, to curb spending growth. Industry support-
ers argue the controls encourage appropriate drug use,
but the public backlash against managed care could
spill over to PBMs if they are seen as too intrusive or
indifferent to consumer needs. At the very least, a
Medicare benefit would encourage closer government
scrutiny of PBM practices, a prospect not unwelcome to
private purchasers. At the worst, Medicare reform
politics could involve the industry in delivering the
benefit but take the teeth out of its cost- and quality-
management capabilities.
This Forum session will bring together speakers
representing large employers, PBM firms, industry
analysts, and health policy experts to discuss the
strengths and limitations of the pharmacy benefit
management model that has evolved in the private
sector and its suitability for a Medicare prescription
drug benefit.
INDUSTRY SNAPSHOT
PBMs administer prescription drug benefits through
contracts with employers, managed health care organi-
zations, and insurance carriers. Today, the top 20 firms
manage more than 90 percent of retail prescription drug
purchases, and three firms—AdvancePCS, Express
Scripts, and Merck-Medco Managed Care—dominate
the market.6 The oldest began as claims administrators.
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Many newer industry members were started or acquired
by health plans, pharmaceutical manufacturers, retail
pharmacy chains, or other PBMs to build specific
capabilities. Still others were established with a particu-
lar niche in mind, such as mail order pharmacy.
A common strength of today’s PBMs is use of
automated processes and information technology.
Electronic communications and real-time claims pro-
cessing are essential to industry operations. The mem-
ber takes a prescription to a participating pharmacy,
where the pharmacist uses a computer to check member
eligibility, the presence of the medication on the plan’s
formulary, plan rules about generic and therapeutic
substitutions, and the member copayment. Other
techniques pioneered by PBMs, including standardized
claim forms and mail order pharmacy, have helped
make the industry a leader in administrative efficiency.
Contractual relationships with retail pharmacies,
pharmacists, wholesalers, and pharmaceutical manufac-
turers are another reason for the industry’s growth.
PBMs negotiate drug price and dispensing fee discounts
with retail pharmacies. They frequently provide incen-
tives to pharmacists to encourage generic drugs and
formulary compliance and negotiate price discounts
with drug manufacturers and wholesalers for mail order
services. The principal sources of net revenue for PBMs
are retained rebates and the difference between drug
acquisition cost and sales cost for mail service phar-
macy, according to industry experts.
Contracts with manufacturers are beginning to
come under closer scrutiny, however. PBMs contract
with manufacturers for rebates (after sale discounts)
based on demonstrated market share utilization shifts.
Rebates range between 2 and 20 percent of the drug’s
average wholesale price, according to Bridget Eber,
Pharm.D., who is practice leader, prescription bene-
fits, for Hewitt Associates.7 Variance is attributed to
competition within therapeutic categories and the type
of formulary, among other factors.
Most employers contracting with PBMs receive a
share of between 50 and 100 percent of the rebate. But
PBMs often receive several forms of income from
manufacturers, including unrestricted financial grants
and fees for disease management programs, rebate
administration, and analysis of drug expenditure data.
While industry experts are aware of these arrangements,
few details are available because of their proprietary
nature. Purchasers are beginning to question whether
they are getting sufficient value for the price they pay
for PBM services.
PBM MANAGEMENT TECHNIQUES
Basic management techniques include pharmacy
network management, formulary management, drug
utilization management, and mail service. Many PBMs
also provide disease management programs. The
extent to which these techniques are used in combina-
tion with member cost-sharing affect drug cost and
utilization trends. In specifying their prescription drug
benefit plans, which are administered by the PBM,
employers balance cost-containment opportunities
with employee satisfaction, convenience, and access
to affordable drug therapies.
Pharmacy Network
PBMs offer a range of broad to narrow retail phar-
macy networks. A narrower network concentrates
purchasing power by limiting the pharmacies at which
members are covered, thereby leveraging greater
discounts. Thirty-one states have “any willing provider”
laws requiring PBMs to contract with any pharmacy
willing to accept their reimbursement rate.8
Formulary
The formulary is a fundamental tool for the PBM.
It is a list of the plan’s preferred drugs within each
therapeutic class. Formulary options range from the
least restrictive open formulary to the most restrictive
closed formulary. Managed formularies combine
member cost-sharing incentives with the list of pre-
ferred drugs to encourage their use. Three-tier and
four-tier cost-sharing structures are becoming popular
because they allow for an open formulary while
requiring higher member contributions for non-
preferred drugs.9
Drug Utilization Review
Prospective, concurrent, and retrospective drug
utilization reviews are used to ensure safety, improve care
quality, and promote compliance with the formulary. Prior
authorization is a form of prospective review, conducted
before medications are dispensed and, ideally, before they
are prescribed. Prior authorization programs target
specific drugs and require special authorization at the
point of sale for coverage by the plan. Most often, the
programs apply to drugs that are high-cost and have off-
label uses and a potential for misuse.
Concurrent reviews are done electronically before
medications are dispensed. The prescription is checked
against the formulary as well as the member’s eligibility,
prescription record for drug interaction, drug-disease
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interaction (when available), appropriate dosage, and
other factors. The pharmacist may receive one of two
types of alerts (or edits) regarding the transaction. The
first does not allow the transaction to proceed. The
second allows the transaction to be processed and
provides information to the pharmacist. Based on the
information, the pharmacist may contact the prescribing
physician before proceeding or after the transaction is
processed.
Retrospective reviews encourage compliance with
the formulary and promote safety by revealing inappro-
priate prescribing patterns. It can also be used to assess
prescribing behavior against best medical practice.
Often, physicians who frequently prescribe drugs that
are not on the formulary are contacted in writing.
Generic Substitution and Drug Interchange
Substitution of generic drugs for their brand name
equivalents is common and cost-effective. Therapeutic
interchange is the substitution of one drug for another
in the same therapeutic class. The technique encourages
formulary compliance. However, physician permission
to interchange drugs is required due to differences in
drug chemical compounds.
Mail Services
Dispensing medications by mail is cost-effective for
maintenance drugs because of discounts negotiated with
wholesalers and manufacturers and the absence of retail
pharmacy overhead. Member communications and a
range of benefit design options are used to encourage
members to use mail service when appropriate. Some
PBMs own and operate their own mail order pharma-
cies, while others outsource the service. Many PBMs
allow members to refill maintenance medications via
the Internet.
Disease Management
Many PBMs provide disease management programs
for common and potentially high-cost conditions, such
as asthma, diabetes, heart disease, and depression.
Often education and disease-specific information are
available to members. Sometimes members are encour-
aged through targeted communications to comply with
their treatment regimens and to take an active role in the
management of their conditions. Some PBMs are
reconsidering their disease management programs due
to sensitivity about medical confidentiality; others are
reassessing programs as a result of marginal success in
reaching target populations.
LEADING-EDGE PBM PRACTICES
Leading-edge practices use the industry’s technol-
ogy and data management competencies to put informa-
tion and tools into the hands of physicians and consum-
ers. One example is the recently announced RxHub
LLC, a joint venture of AdvancePCS, Express Scripts,
and Merck-Medco Managed Care to create an elec-
tronic exchange and encourage more physicians to
prescribe electronically.10
The venture addresses three major health policy
concerns: safety, quality, and consumer service. It
attempts to enhance safety by reducing errors intro-
duced by reading handwritten prescriptions. Quality is
addressed by making available to physicians the PBM’s
database and its quick access to information such as
drug interactions. And it targets consumer inconve-
nience by providing information to physicians at the
point of care instead of catching problems, such as
noncompliance with the formulary or incorrect dosage,
at the pharmacy. The program is currently being tested
with physicians. The three PBMs plan to introduce the
exchange in late 2001or early 2002.
To be sure, physician acceptance and connectivity
will be necessary for the exchange’s success. Many
doctors use the Internet now, although primarily for
administrative transactions and clinical research.11
Fewer than 5 percent prescribe electronically, according
to the RxHub venture partners.
Yet, despite the potential for improved safety and
efficiency, the venture is raising concerns among chain
and independent pharmacies. They believe RxHub will
shift patients from retail pharmacies to the partners’
mail order and Internet services. The PBM partners
maintain RxHub is merely a standardized electronic
platform for prescription writing. Physicians will be
able to transmit prescriptions to the patient’s pharmacy
of choice. Another concern of some smaller pharmacies
is a burdensome investment in information technology
in order to receive prescriptions electronically.
New PBM consumer tools can tap into the power of
the Internet for convenient, customized access to health
and prescription drug information. Two-thirds of employ-
ers with 20,000 or more employees use Internet/intranet
applications for medical benefits.12 PBMs are following
suit by providing plan members with online information
and tools to help them effectively use their prescription
drug benefits and manage their health.
PBMs are also dedicating more resources to clinical
consulting. Their pharmacists meet face-to-face with
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physicians and other health care professionals to
provide clinical information about prescription drugs
and treatment protocols. Often, clinical consultants can
work from a profile of the physician’s prescribing
practices to tailor the consultation.
Finally, leading PBMs are positioning themselves as
comprehensive health management organizations
providing a wide range of research and health improve-
ment services. One example is the Center for Healthy
Aging and Drug Safety at AdvancePCS. The firm is
dedicating staff and resources in a “holistic approach to
promoting safe and cost effective health care by adding
the consumer as an active participant in his/her own
health care,” according to Renwyck Elder, R.Ph., vice
president for strategic business consulting. The center
researches aging and drug safety issues and educates
consumers, physicians, and pharmacists. Its mission is
to influence the overall cost of care by facilitating
reductions in direct and indirect costs.
EMPLOYER-SPONSORED PLANS
Forty-eight percent of employers with more than
10,000 employees contract directly with a PBM,
according to a recent survey by consulting firm William
M. Mercer.13 Each employer’s prescription drug plan is
different with respect to coverage and elements such as
utilization controls and disease management. However,
employers interviewed for this brief expressed similar
expectations of their PBMs: smooth plan administration
with advanced use of technology and good internal
controls; best practice clinical management programs,
including provider initiatives and effective drug utiliza-
tion review programs; favorable financial terms; excel-
lent customer service; and PBM willingness to partner
on areas of need or interest.
Contracted Services
Large employers contract with PBMs for a fairly
similar set of pharmacy benefit management services:
administrative services, pharmacy network manage-
ment, formulary management, rebate services, drug
utilization management, and mail service. In contrast,
health plans may contract with PBMs for administrative
services and drug utilization review but manage their
own formularies and negotiate their own discounts.
Most PBMs contracting with employers forecast
expenditures and consult with employers on plan
design. Employers make basic decisions about the
restrictiveness of the formulary and the degree to which
prescription drug management techniques are used to
promote formulary compliance.
Administrative services usually include maintaining
eligibility files, issuing identification cards, member
services, reporting, and processing claims consistent
with plan design by adhering to coverage rules, such as
formulary and prior authorization, and member cost-
sharing in the form of deductibles, copays, coinsurance,
and benefit maximums.
In addition to concurrent and retrospective reviews,
drug utilization management often encompasses imple-
mentation of best practice clinical management pro-
grams, health and disease management programs, case
management, physician initiatives, and member educa-
tion and outreach programs.
With a growing number of breakthrough drugs
coming to market and increased direct-to-consumer
advertising, more employers are asking their PBMs to
provide them a formal clinical review of new drugs.
The review includes recommendations for placement in
the formulary and for encouraging appropriate utiliza-
tion through controls such as prior authorization, retail
edits, quantity limitations, and member cost-sharing.
Typically, large employers contract with only one
PBM because discounts and administrative fees are
based on projected group utilization. Generally, they opt
for a broad pharmacy network, and contracts usually
cover a three-year term. The various criteria employers
consider in choosing a PBM are summarized in Table 1.
Table 1
Choosing a PBM: 
Employers’ Administrative, Service,
and Financial Criteria
 Bidding requirements (e.g., eligibility file
maintenance)
 Firm profile and stability
 Operational and administrative procedures
 Network management
 Utilization and cost management
 Financial terms
 Performance guarantees
 Miscellaneous administrative requirements
 References
Source: Bridget Eber, Hewitt Associates
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Financial Terms
The typical payment arrangement for employers
contracting with PBMs is a fee-per-claim basis. Admin-
istrative fees have been declining in recent years,
averaging between 10 cents and 60 cents per claim.
Financial terms considered during the bid process
include administrative and dispensing fees, rebates, and
price discounts on drug average wholesale price and
maximum allowable cost, a reimbursement schedule for
generic drugs. Base rate administrative fees often do not
include fees for customized programming of systems
administering utilization controls such as prior authori-
zation programs. Contracts often contain provisions
prohibiting employers from discussing negotiated fees
and discounts with other employers.
Performance Evaluation and
Financial Guarantees
Contracts usually specify performance on several
factors. For example, dispensing indicators may address
mail service rate, timeliness, accuracy, and generic drug
rate. Customer service indicators may include telephone
accessibility, response time on written inquiries, and
timely and accurate issuance of identification cards.
Employers typically approach PBM performance
evaluation in a three-step process. First, they identify
areas of importance, such as customer service, generic
rate, or mail service timeliness and accuracy. Next, they
consider financial incentives. Usually a percentage of
the administrative fee (20 to 50 percent) guarantees
performance. Sometimes a limited risk-sharing arrange-
ment is used so that PBMs and employers share any
savings. Finally, they structure the financial guarantee
by establishing targets and defining measures and
incentive/penalty arrangements.
Audits
Audits are used to formally verify PBM performance.
The audit provides oversight, ensuring that the PBM
meets its contractual agreements, as well as information
on utilization and PBM operations and performance. A
recent survey found that 68 percent of employers have
audit rights in their contracts, but only 30 percent audit
their PBMs.14 PBM audits are becoming more frequent,
however, and employers are incorporating more detailed
audit language into their contracts. New provisions more
clearly define audit rights, such as choice of auditor,
time frame for responding to requests, and ownership
and use of data. As part of the process, PBMs must audit
participating pharmacies at their own cost.
EMPLOYER PERSPECTIVES AND
LESSONS LEARNED
A recent survey of employers by the International
Society of Employee Benefits Specialists reported that
91 percent of respondents said they were satisfied or
very satisfied with their PBMs.15 Discussions with
employers and benefit consultants provide more detail
on employer perspectives about PBM strengths, areas
for improvement, and lessons learned. Although em-
ployers acknowledge PBMs have different management
strategies and strengths, they articulate some common
themes about performance.
Strengths
Administrative Services. Employers report PBMs
efficiently and economically manage a high volume of
claims with relatively few problems for beneficiaries. For
example, one large employer interviewed for this brief
reports that 400,000 prescription drug claims are pro-
cessed annually. AdvancePCS, one of the three largest
firms, manages 450 million pharmacy claims annually,
representing $18 billion in drug expenditures.16 Nowhere
else in the health care delivery system is such a large
volume of claims processed in real time so efficiently.
Negotiated Discount Pricing on Drugs and Net-
works. PBMs are effective at negotiating rebates from
manufacturers and lower prices from retail pharmacies
(drugs and dispensing fees) for plan members than are
available to cash-paying customers.
Drug Utilization Review. PBM databases are com-
prehensive. They provide real-time safety controls and
the potential to continually improve efficiency and
care quality.
Mail Service. Audits of mail order services reveal they
are efficient and secure. Plan members, rather than
sponsors, are usually the primary beneficiaries of
savings associated with mail service due to the deep
discounts offered to encourage their use. For example,
the retiree drug plan might have a 20 percent coinsur-
ance for a 30-day supply at retail and $10 generic/$20
brand copays for a 90-day supply by mail. Employers
are reexamining plan design to ensure it does not
overemphasize mail service and result in wastage of
medications and unnecessary spending. They want to
avoid problems such as a beneficiary’s buying a 90-day
supply of a maintenance drug only to have problems
with side effects and never finish the course of medica-
tion. Some employers require at least two prescription
fills through retail before allowing or requiring the
prescription to be processed by mail.
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Areas for Improvement
Client-Focused Infrastructure and Reporting. A
number of employers express dissatisfaction with PBM
reporting, saying they have difficulty understanding the
data. Employers also want reports tailored to specific
interventions. Generally, PBMs will not customize
reports without charging additional fees. For their
largest clients, the cost of customized systems and
reporting is usually included in the bidding process.
A related issue employers raise is member service.
Especially during the first quarter of a plan year with
new coverage rules, employers report that members are
frequently directed back to them rather than having
issues resolved by the PBM. As large corporations
reduce the size of their benefits staff, the problem is
becoming more pronounced. Employers want PBMs to
use more sophisticated information and reporting
systems so that member service representatives can
readily reference coverage rules and reports can be
customized. They also want better handling of member
inquiries, especially when delivering unwelcome
messages, and better execution of appeals processes.
Industry leaders are aware of employer concerns and
are responding in a variety of ways. For instance, some
PBMs are experimenting with electronic venues to
customize reports. Employer-clients would have a
database available to them and could customize their
own reports. PBMs are also distilling data into action-
able information and creating reports consistent with
plan objectives, rather than reporting a lot of data that
may be meaningless to the client. PBMs and their
clients are continuing to work together to improve
reporting and customer service.
Proactive Programs. Employers want PBMs to more
actively address physician prescribing patterns and
pharmacy performance to encourage best clinical
practice. The lack of proactive account management
relative to cost management and quality improvement
opportunities is a common employer complaint.
For example, Verizon Communications, working
with Omnicare, Inc., a geriatrics health care company,
found a significant number of Verizon’s Medicare-
eligible retirees were being prescribed cisapride, a
gastroesophageal reflux disease medication with
adverse side effects for many seniors.17 They also found
their PBM did not have a drug utilization review
protocol to caution against cisapride use in seniors,
even though there are alternatives with significantly less
risk. Omnicare pharmacists consulted with prescribing
physicians in an effort to reduce the risk of cisapride-
associated problems in plan members with medical and
drug risk factors. The effort resulted in cisapride being
discontinued in 78 percent of identified cases.
Another example is an effort led by General Motors
(GM) to improve treatment compliance and drug effect
through dosing optimization. GM’s director of phar-
macy, health care initiatives, Cynthia Kirman, PharmD.,
has met with hospitals, health plans, PBMs, medical
societies, employers, and drug manufacturers to stimu-
late awareness and education about the quality and cost
implications of once- versus twice-daily dosing. GM is
working with Merck-Medco Managed Care on develop-
ing a pilot program to improve optimal dosing for
maintenance drugs obtained through mail service.
Employers recognize that payment on a per claim
basis does not provide PBMs an incentive to improve
clinical practice. Some are exploring more aggressive
risk-sharing arrangements such as performance-based
pharmacy networks. Others are excluding rebate
guarantees from their contracts to reduce incentives
driving utilization toward specific drugs.
Lessons Learned
Employers interviewed for this issue brief generally
agree that they would offer the following advice to
others considering contracting with PBMs.
Recognize that not all PBMs are alike. Most PBMs
evolved with a focus on a particular market segment
and therefore developed specific management strategies
and strengths. For example, a PBM may present excel-
lent financial terms but not have a strong reputation for
service to pharmacists and physicians. Open reporting
of rebate agreements and processes may be a manage-
ment approach for one firm, but not another. One PBM
may have successful disease management programs,
while another is relatively ineffective in demonstrating
participation by target populations. Although there is a
fairly uniform level of administrative services provided
by industry members, employers must consider a
number of financial, operational, and special program
issues during the bidding and selection process.
Clearly define objectives and contract terms. As
employers gain more experience with PBMs, they are
less likely to use standard PBM contracts. Many em-
ployers are undergoing a comprehensive review of
contract terms to improve clarity. For example, new
contracts clearly define how measures will be calculated
and reported and how penalties will be assessed. They
thoroughly describe audit rights and what constitutes a
rebate. Financial terms are being renegotiated with
 8
 
greater use of incentive/penalty arrangements. More
employers are working with consultants familiar with
PBM operations in order to improve their knowledge
and position prior to contracting.
Formally review performance. Although it can be
expensive, more employers are auditing their PBMs.
Occasionally, audits find errors such as incorrect fees or
discounts programmed at set-up that result in financial
charges to the PBM. Some employers report that an
audit revealed a PBM practice they did not track in
routine reports, such as therapeutic substitutions at mail
service. The Segal Company, an actuarial and consult-
ing firm, finds formal PBM reviews and audits often
“provide encouraging news about PBMs,” such as
higher than expected generic substitution rates and
larger discounts than required by the contract.18
Actively communicate with plan members. Leading
employers believe the more informed employees and
retirees are about their prescription drug benefit, the
less likely they will have problems. At a minimum,
members should understand the objectives of the
prescription drug plan and know what drugs are on the
formulary and what techniques are used to promote
formulary compliance.
Changes in coverage or processes present special
communication challenges. Drug price changes are espe-
cially difficult to communicate in a timely way.
Employers devote significant resources to benefits
communication. They actively educate employees and
retirees through a variety of venues about their benefit
plans, navigating the health care system, and health
promotion/disease management. PBMs, through con-
tractual agreements, are also responsible for educating
plan members. They use multiple media to reach out to
members and respond to their inquiries. They also prepare
network pharmacies to answer plan member questions.
Growing Concerns about Manufacturer
Relationships
As prescription drug spending continues to climb at
double-digit rates, more employers have questions
about the effects of PBM/manufacturer relationships.
Speaking candidly, they worry that manufacturer
pricing and rebate agreements may inappropriately
drive formulary and drug switching decisions and
excessive use of drugs. There is no objective evidence
linking rebates to inappropriate volume increases or
drug substitutions to consumer harm or benefit. But
PBMs do not disclose details of rebate negotiations and
other revenue from manufacturers, fueling speculation
about the actual effects of those agreements. Jim
Astuto, regional manager with the healthcare manage-
ment group at Verizon Communications, speaks for
many employers when he asks, “Are we getting dis-
count prices while driving increased volume?”
Until recently, few employers were interested in
drug formulary management. Employers are reluctant to
involve themselves in areas where they have little
expertise. After making basic decisions about formulary
restrictiveness and enrollee cost-sharing, they rely on
the PBM and its pharmacy and therapeutics (P&T)
committee to recommend a quality formulary. The P&T
committee usually comprises physicians and clinical
pharmacists and is often independent of the PBM. Their
recommendations are based on evaluations of drug
efficacy, safety, and relative cost. Drug side effects and
their relationship to physician visits, clinical monitor-
ing, and patient functioning are considered when
determining relative cost.
Many P&T committees use what Joanne Sica,
assistant vice president of Aon Consulting, refers to as
a “bucket strategy.”19 The first bucket contains “must
have medications.” The second bucket contains “no
need to have medications.” These drugs either have no
clinical advantage over others in the same therapeutic
class or have safety or efficacy profiles that are not
comparable to others in the class and/or have a higher
price. The third bucket contains “could have medica-
tions.” These have similar safety, efficacy, and relative
cost as other drugs in the therapeutic class and are good
clinical alternatives for many patients.
Once determinations are made on “must have” and
“no need to have” drugs, the committee may provide
guidance on the “could have medications” and the
number of choices physicians should have within a
therapeutic class. Otherwise, their work is complete. The
PBM then negotiates price and rebate agreements on the
“could have medications.” Whether those drugs end up
on the formulary may be due more to the capabilities of
the PBM’s rebate contracting department than to clinical
significance, according to some industry experts.
Some PBMs report a somewhat different P&T
committee process. Among others, the Merck-Medco
Managed Care P&T committee does not use cost as a
factor in its considerations. Drug price is negotiated by
the PBM based on its ability to move market share. It
does not enter into P&T committee deliberations.
Rebate negotiations seem to be getting more com-
plex. Negotiating a rebate for one drug often necessi-
tates having other of the manufacturer’s drugs on the
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Copayments 78%
Coinsurance 17%
Both 5%
None <1%
Source: International Society of Employee Benefit Specialists, Survey Results,
December 2000.
formulary. Manufacturers may also require demon-
strated market shifts to qualify for rebates. The PBM’s
use of the formulary to shift utilization gives them
better leverage to negotiate prices and rebates from
manufacturers. But there are numerous questions about
that strategy, such as whether drug switching decisions
are in the best interest of individual consumers and how
physicians view therapeutic substitution requests and
other, perhaps numerous, PBM formulary advisories.
Employers play a part in the problem by accepting
discounts and using rebate performance guarantees. In
this competitive environment, however, most employers
are reluctant to give up rebates when everyone else
benefits from them and there is no hard evidence of
detrimental utilization effects.
CONSIDERATIONS FOR MEDICARE
As Congress considers expanding Medicare benefits
to include outpatient prescription drugs, large employer
experiences highlight important considerations for
Medicare policy.
Expenditure Trends and
Patient Affordability
Prescription drug costs as a percentage of total health
care expenditures will continue to rise and older Ameri-
cans will continue to account for a disproportionate
share of drug spending. In 2000, drug spending rose by
19 percent to almost $132 billion. A recent study by the
Health Care Financing Administration predicts prescrip-
tion drugs will be a major driver of annual health care
spending increases averaging 13 percent over the next
decade.20 Medicare beneficiaries will spend an estimated
$686 out-of-pocket on drugs in 2001, and 20 percent of
them will spend more than $1,100.21
Employer experiences bear out these data. The drug
benefit is the fastest rising component of retiree medical
plan costs. A survey of large employers predicts retiree
drug costs will increase 23 percent in 2001, compared
to a 13 percent rise in total retiree medical plan expen-
ditures.22 One employer interviewed for this brief
reports that Medicare-eligible retirees use an average of
34 prescriptions per year, while the average for active
enrollees is 11 percent.
More work is needed to understand PBMs’ capabil-
ity to affect drug prices, expenditures, and trends. A
1997 U.S. General Accounting Office study of the
Federal Employees Health Benefits Plan estimated
significant savings from PBMs, although much of the
savings came from “lower prices paid to pharmacies
rather than rebates offered by drug manufacturers.”23
Private employer experiences show PBMs exert
more control over expenditures and trends than an
unmanaged system does, but on the whole are unsuc-
cessful in slowing spending growth. PBMs counter they
could further slow spending if permitted to use more
aggressive pharmacy management strategies, but
employers are unwilling to do so.
Nevertheless, after almost a decade of annual
double-digit growth in prescription drug expenditures,
employers are increasing copays for brand and generic
drugs. And more employers are considering shifting
consumer cost-sharing from a copay to a coinsurance
design. As shown in Figure 1, copayment accounts for
more than three-quarters of current cost-sharing struc-
tures. The copay design, a flat fee paid by plan mem-
bers for a prescription, such as $5 for generic and $10
for brand drugs, has resulted in employers’ paying an
increasing share of drug costs as prices have increased.
The coinsurance design requires plan members to pay
a percentage, usually 20 percent, of the prescription
cost. Coinsurance designs automatically index member
out-of-pocket spending to the drug’s cost and may make
consumers more aware of prices for different brand and
generic drugs.
Figure 1
Employer/Employee Cost-Sharing Structures
The Role of the PBM
The way the PBMs’ role is defined and the flexibil-
ity they are given to use techniques such as formulary
management and drug utilization review will likely
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determine their effectiveness in containing costs and
improving the way patients use and physicians prescribe
drugs. However, just as there is a public backlash
against managed care, there may be problems if PBMs
are perceived by consumers and physicians as being too
intrusive.
Such sentiment is evident in New Jersey, where
new regulations effective July 1, 2001, prohibit health
maintenance organizations from using a closed formu-
lary or denying coverage for drugs not on their pre-
ferred list. The new rules also limit plan member and
physician incentives to choose preferred drugs.24
Citing such examples, policy experts speculate about
the appropriateness of the current private-sector model
for Medicare. Coverage decisions and processes in a
Medicare benefit would need to be more public and
subject to greater scrutiny. Some industry experts
propose a fairly regulated approach to PBMs adminis-
tering Medicare benefits, with open formularies,
reference (or incentive) drug pricing, and periodic
bidding for regional monopoly contracts. Others recom-
mend a more competitive model, whereby seniors
would choose among approved PBMs in their market.
Still others, such as the National Association of
Chain Drug Stores (NACDS), question the scope of
patient care and cost management responsibilities
assigned to PBMs in Medicare drug proposals under
consideration. NACDS would limit the PBM role to
administrative functions, saying they have not been
effective care managers and actually add cost to the
system.25
Depending on the structure of a Medicare PBM
market, the formulary itself could be a critical sticking
point in designing a workable benefit. Private employ-
ers make important decisions regarding the restrictive-
ness of the formulary and member cost sharing. Will
Medicare play a similar role? If so, how will formulary
decisions be made, and what are the implications of
excluding drugs from the Medicare formulary? On the
other hand, formulary design and compliance incentives
are the key tools for containing costs. How would
program spending be managed with an open formulary
and few rules or incentives for preferred drugs?
PBMs and Financial Risk
Typically, PBMs contracting with employers are
paid by a fee-for-service arrangement. They generally
do not guarantee drug spending trend or take capitated
risk. They do, however, negotiate financial guarantees
for certain aspects of the plan, such as generic dispens-
ing rates and rebates. In recent years, PBMs experi-
mented with capitated arrangements. These were
quickly abandoned for a variety of reasons: PBMs are
not insurers, they have not been able to accurately
project cost trends, and they do not have contractual
relationships with physicians and therefore have little
ability to influence prescribing. Generally, proposals to
shift Medicare’s insurance risk for pharmacy to the
PBM industry through full capitation have met with a
cool reception. But, since the Medicare prescription
drug bill passed by the House last year was based on
capitation, the issue of risk assumption by PBMs has
continued significance.
Marketplace Relationships and Dynamics
Finally, Congress must consider how a Medicare
benefit administered by PBMs affects marketplace
relationships and dynamics. For example, retail pharma-
cies say increased PBM market share disproportionately
targets them for cost containment through low reim-
bursement rates. Another competitive issue they raise is
the redirection of consumers to mail order and Web-
based pharmacy services. While mail order and online
pharmacies may be a convenience for consumers, the
long-term impact on retail pharmacies is unknown.
THIS FORUM SESSION
Speakers
Bridget Eber, Pharm.D., who leads Hewitt Associ-
ates’ national prescription drug consulting practice, will
begin with an overview of the PBM industry and a dis-
cussion of the principles and “rules of the road” that
generally guide large-employer contracting decisions.
Before joining Hewitt, Eber was a regional pharmacy
director for a large national HMO, where she was res-
ponsible for administrative and cost management pro-
grams. She has also practiced as a clinical pharmacist.
Cynthia Kirman, Pharm.D.,  director of pharmacy,
health care initiatives, at General Motors, will discuss
GM’s experience with pharmacy benefit management
and outline current GM pharmacy initiatives, with a
focus on retiree issues. In her role at GM, Kirman, a
registered pharmacist, works with insurance carriers,
unions, and community leaders to improve prescription
drug value and quality.  Her previous professional
experience includes serving as director of pharmacy
programs for a health maintenance organization and as
director of clinical information services for a pharmacy
benefit management company. 
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Key Questions
Among the questions to be considered by the
speakers are the following:
 How effective are rebates for cost containment? And
to what extent do purchasers actually pay the aver-
age wholesale price? If PBMs manage most of
prescription drug purchases, can they all be getting
discounts from the “average” price?
 What would be the role of PBMs in a Medicare
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make cost containment, utilization management, and
formulary decisions? If PBMs were given little
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how would costs be managed?
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 How would a Medicare benefit administered by
PBMs affect marketplace dynamics and relation-
ships among PBMs, retail pharmacies, manufactur-
ers, and health plans? How would the benefit affect
competition for PBM services, considering there are
other companies with similar management capabili-
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 In designing the benefit, how can Congress capital-
ize on industry information management capabilities
to improve drug safety and efficiency?
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